11 recruiting, 4 unknown, 3 not yet recruiting, 3 terminated. 14 Phase 1, 10 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Recruiting 7, Not yet recruiting 3, Terminated 3, Completed 1 |
| Phase 2 | 10 | Recruiting 4, Unknown 3, Not yet recruiting 2, Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow RAS Mutation: new trials by email Literature Review of RAS Mutation trials Research Report on RAS Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation. GFH276, with or without Tislelizumab, Pemetrexed - RAS Mutation, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 84 | 2026-11-01 | 2026-09-29 |
| TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients vopimetostat, ERAS-0015 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | Tango Therapeutics, Inc. | 188 | 2026-11-01 | 2026-10-27 |
| Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations ASKC189 - Solid Tumor, RAS Mutation | Phase 1 | Not yet recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 200 | 2026-09-30 | 2026-09-23 |
| A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression Intravenous AN4035, Intravenous AN4035 followed by intravenous EGFR Inhibitor. - Solid Tumor (Phase I), RAS Mutation | Phase 1 | Recruiting | Adlai Nortye Biopharma Co., Ltd. | 228 | 2026-09-23 | 2026-10-16 |
| A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations BG-85738, Tislelizumab, Cetuximab - RAS Mutation, Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 100 | 2026-09-02 | 2026-10-23 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations AN9025 oral capsule - Solid Tumors (Phase 1), RAS Mutation | Phase 1 | Recruiting | Adlai Nortye Biopharma Co., Ltd. | 118 | 2026-01-28 | 2026-06-08 |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 183 | 2025-05-31 | 2026-10-23 |
| Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway DCC-3084 - Advanced Solid Tumor, RAF Mutation | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 29 | 2024-05-14 | 2026-03-05 |
| ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC irinotecan, cetuximab, envafolimab - RAS Mutation, Metastatic Colorectal Cancer | Phase 2 | Recruiting | Beijing Hospital | 60 | 2024-03-01 | 2026-07-28 |
| PAS-004 in Patients With Advanced Solid Tumors PAS-004 Capsules, PAS-004 Tablets - RAS Mutation, NF1 Mutation | Phase 1 | Recruiting | Pasithea Therapeutics Corp. | 83 | 2024-02-29 | 2026-10-30 |
| Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer Cadonilimab + bevacizumab + FOLFOX - Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma | Phase 2 | Recruiting | Fudan University | 53 | 2024-01-01 | 2024-01-23 |
| Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab - RAS Mutation, Ras (Kras or Nras) Gene Mutation | Phase 2 | Unknown | N.N. Petrov National Medical Research Center of Oncology | 20 | 2023-10-03 | 2024-01-29 |
| Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. ABM-168 - Advanced Solid Tumor, RAS Mutation | Phase 1 | Terminated | ABM Therapeutics Corporation | 12 | 2023-03-30 | 2024-12-06 |
| NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) OKI-179 + binimetinib - RAS Mutation, NRAS Gene Mutation | Phase 1 / Phase 2 | Completed | OnKure, Inc. | 36 | 2022-05-11 | 2025-03-07 |
| Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors Tovorafenib, Tovorafenib Drug: Pimasertib - Melanoma, Solid Tumor | Phase 1 | Terminated | Day One Biopharmaceuticals, Inc. | 44 | 2022-05-02 | 2025-08-14 |
| Centralized Tumour Board and Secondary Intervention Rate in mCRC Virtual centralized multidisciplinary tumour board - Metastatic Colorectal Cancer, RAS Mutation | Unknown | Ludwig-Maximilians - University of Munich | 130 | 2021-06-01 | 2021-04-21 | |
| PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC oxaliplatin+capecitabine+bevacizumab+PD-1 antibody - Colorectal Cancer, RAS Mutation | Phase 2 | Unknown | Chinese PLA General Hospital | 40 | 2021-05-26 | 2024-04-30 |
| Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB Bevacizumab, Cetuximab, 5-FU - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | Active not recruiting | Azienda USL Reggio Emilia - IRCCS | 280 | 2021-04-30 | 2026-07-24 |
| A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies RSC-1255 Dose Escalation, RSC-1255 Dose Expansion - Advanced Malignant Solid Neoplasm, RAS Mutation | Phase 1 | Recruiting | RasCal Therapeutics, Inc. | 134 | 2021-03-03 | 2026-06-23 |
Showing 20 of 23. Sign in to see all of them.
Colorectal Neoplasms (9) · Lung Neoplasms (5) · Melanoma (5) · Pancreatic Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Neoplasms (3) · Glioblastoma (2) · Astrocytoma (1) · Brain Neoplasms (1) · Cardiofaciocutaneous syndrome (1) · Colonic Neoplasms (1) · Costello Syndrome (1) · Disease Progression (1) · LEOPARD Syndrome (1) · Legius syndrome (1)
Neoplasms (15) · Neoplasms by Site (15) · Colonic Diseases (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Gastrointestinal Diseases (10) · Gastrointestinal Neoplasms (10) · Intestinal Diseases (10) · Intestinal Neoplasms (10) · Rectal Diseases (9) · Lung Diseases (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8) · Neoplasms by Histologic Type (7)
Cetuximab (4) · Bevacizumab (3) · Irinotecan (3) · Fluorouracil (2) · Leucovorin (2) · tislelizumab (2) · Carboplatin (1) · Cisplatin (1) · Folfox protocol (1) · Gemcitabine (1) · Immune Checkpoint Inhibitors (1) · Leflunomide (1) · Oxaliplatin (1) · Pemetrexed (1) · Taxes (1)
Adlai Nortye Biopharma Co., Ltd. (2) · Genfleet Therapeutics (Shanghai) Inc. (2) · Tango Therapeutics, Inc. (2) · ABM Therapeutics Corporation (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda USL Reggio Emilia - IRCCS (1) · BeOne Medicines (1) · Beijing Hospital (1) · Children's Hospital Medical Center, Cincinnati (1) · Chinese PLA General Hospital (1) · Day One Biopharmaceuticals, Inc. (1) · Deciphera Pharmaceuticals, LLC (1) · Fudan University (1) · Jiangsu Aosaikang Pharmaceutical Co., Ltd. (1) · Ludwig-Maximilians - University of Munich (1)
United States (9) · China (6) · Australia (3) · Bulgaria (1) · Canada (1) · France (1) · Italy (1) · New Zealand (1) · Romania (1) · Russia (1)
Erika Gervasi (1) · Evgeny Imyanitov (1) · Guanghai Dai, MD (1) · Irene De Simone (1) · Kartik Krishnan, MD, PhD (1) · Kathryn N Weaver, MD (1) · Maxim Pimpkin, MD, PhD (1) · Michael Mann, MD (1) · Ryan Sullivan, MD (1) · Volker Heinemann, Prof. (1) · Ying Yuan, MD (1) · Ziming Li, MD (1)